UDRIVE D51.1 eUropean naturalistic Driving and Riding for Infrastructure and Vehicle safety and Environment

The aim of Task 5.1 is to identify and select, among the outcomes of SP4, the results that are relevant to infer recommendations for measures improving road safety and sustainability. Due to time constraint, the analyses and the recommendations have been done in less time that it was planned at the beginning of the project. The key outcomes of the SP4 work with particular reference to crash risk, unsafe driving, and eco-driving will be studied and organized in terms of relevance to safety and sustainability policies and potential actions towards road users, vehicle and road. Recommendations have been developed to propose actions to stakeholders that can be implemented in the near future to increase safety and sustainability of road transport. This work integrates several reviews of different measures implemented previously in France, Germany, Netherlands and United Kingdom in terms of road safety measures. Then, the recommendations consider possible updates of existing measures and the development of new measures

UDRIVE D51.1 eUropean naturalistic Driving and Riding for Infrastructure and Vehicle safety and Environment

The aim of Task 5.1 is to identify and select, among the outcomes of SP4, the results that are relevant to infer recommendations for measures improving road safety and sustainability. Due to time constraint, the analyses and the recommendations have been done in less time that it was planned at the beginning of the project. The key outcomes of the SP4 work with particular reference to crash risk, unsafe driving, and eco-driving will be studied and organized in terms of relevance to safety and sustainability policies and potential actions towards road users, vehicle and road. Recommendations have been developed to propose actions to stakeholders that can be implemented in the near future to increase safety and sustainability of road transport. This work integrates several reviews of different measures implemented previously in France, Germany, Netherlands and United Kingdom in terms of road safety measures. Then, the recommendations consider possible updates of existing measures and the development of new measures

Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

Background: The added value of radiotherapy following neoadjuvant FOLFIRINOX chemotherapy in patients with resectable or borderline resectable pancreatic cancer ((B)RPC) is unclear. The objective of this meta-analysis was to compare outcomes of patients who received neoadjuvant FOLFIRINOX alone or combined with radiotherapy. Methods: A systematic literature search was performed in Embase, Medline (ovidSP), Web of Science, Scopus, Cochrane, and Google Scholar. The primary endpoint was pooled median overall survival (OS). Secondary endpoints included resection rate, R0 resection rate, and other pathologic outcomes. Results: We included 512 patients with (B)RPC from 15 studies, of which 7 were prospective nonrandomized studies. In total, 351 patients (68.6%) were treated with FOLFIRINOX alone (8 studies) and 161 patients (31.4%) were treated with FOLFIRINOX and radiotherapy (7 studies). The pooled estimated median OS was 21.6 months (range 18.4–34.0 months) for FOLFIRINOX alone and 22.4 months (range 11.0–37.7 months) for FOLFIRINOX with radiotherapy. The pooled resection rate was similar (71.9% vs. 63.1%, p = 0.43) and the pooled R0 resection rate was higher for FOLFIRINOX with radiotherapy (88.0% vs. 97.6%, p = 0.045). Other pathological outcomes (ypN0, pathologic complete response, perineural invasion) were comparable. Conclusions: In this meta-analysis, radiotherapy following neoadjuvant FOLFIRINOX was associated with an improved R0 resection rate as compared with neoadjuvant FOLFIRINOX alone, but a difference in survival could not be demonstrated. Randomized trials are needed to determine the added value of radiotherapy following neoadjuvant FOLFIRINOX in patients with (B)PRC